The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
Abstract Recently Food and Drug Administration (FDA)-approved pralsetinib (BLU-667) and selpercatinib (LOXO-292) are RET-selective protein tyrosine kinase inhibitors for treating RET-altered cancers, but whether they have distinct activity was unknown. The L730V/I mutations at the roof of the solven...
में बचाया:
| मुख्य लेखकों: | , , , , , |
|---|---|
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Nature Portfolio
2021-06-01
|
| श्रृंखला: | npj Precision Oncology |
| ऑनलाइन पहुंच: | https://doi.org/10.1038/s41698-021-00188-x |
| टैग: |
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|